What Epiphany does

Epiphany Biosciences is a privately held biotechnology company headquartered in San Francisco, California, founded in 1998. According to the available firmographic data, the company develops therapeutic products and diagnostic technologies intended to prevent or cure the spread of pathogenic viruses, placing it in the antiviral therapeutics and infectious disease diagnostics space.

The company operates with a small headcount of 11–50 employees and is led by founder, chairman, and CEO Fred Volinsky. The firm's only documented material capital event is a March 2007 Series 2 financing of $36 million led by Wexford Capital with participation from CDIB BioScience Ventures. No product approvals, commercial partnerships, clinical trial readouts, or pipeline assets are described in the provided source material, and the company's current operating status, product revenue, and post-2007 corporate activity cannot be confirmed from the available data.

Given the absence of disclosed commercial products, pricing models, customer segments, or distribution channels, the available evidence supports characterization of Epiphany as a small, founder-led, clinical-stage virology R&D entity. The substantial gap between the 2007 funding event and the present suggests either limited public visibility, a quiet operating posture, or a potential stall in disclosed activity, but the input does not allow definitive determination of current commercial trajectory.

Name

Epiphany

Website

https://epiphanybio.com

Company type

Private

Founded year

1998

Headcount range

11–50 employees

Short description

Epiphany Biosciences is a privately held, San Francisco-based biotechnology company founded in 1998 that develops antiviral therapeutics and viral diagnostic technologies aimed at preventing or curing the spread of pathogenic viruses.

Ownership category

akta.pro rank

Product category

Antiviral Therapeutics and Diagnostics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Antiviral therapeutics
• Virus diagnostics
• Biopharmaceutical development
• Infectious disease treatment
• Pathogen detection

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Core offering

Epiphany Biosciences develops therapeutic products and diagnostic technologies focused on preventing or curing the spread of pathogenic viruses. The company combines antiviral drug development with viral detection/diagnostic capabilities to address infectious disease challenges.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Expansion highlights1 record

Direct peers

• Vir Biotechnology: Clinical-stage immunology company developing antiviral therapeutics and platform approaches against serious infectious diseases. Directly comparable to Epiphany as a focused antiviral therapeutics developer with diagnostic-adjacent capabilities.
• Atea Pharmaceuticals: Clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapeutics for serious viral infections including COVID-19 and hepatitis C. Directly comparable to Epiphany's antiviral therapeutic focus and small-cap biotech profile.
• Cocrystal Pharma: Clinical-stage biotechnology company developing antiviral therapeutics that target viral replication using structure-based drug design. Comparable as a small-cap antiviral-focused developer with a therapeutic-only platform.

Broad incumbents

• Gilead Sciences: Large biopharmaceutical company with a leading antiviral franchise (remdesivir, lenacapavir, hepatitis C portfolio) and broad infectious-disease capabilities. Comparable as the dominant incumbent in antiviral therapeutics.
• Moderna: Major biopharmaceutical company developing mRNA-based vaccines and therapeutics for infectious diseases including COVID-19, influenza, and RSV. Comparable in the broader viral infectious-disease therapeutics and vaccines space.
• BioNTech: Major biopharmaceutical company developing mRNA vaccines and immunotherapies for infectious diseases and oncology. Comparable as a leading developer of vaccines targeting viral pathogens.
• Regeneron Pharmaceuticals: Large biopharmaceutical company developing antibody-based therapeutics for infectious diseases including Ebola and COVID-19 (REGEN-COV). Comparable as a developer of antiviral biologics.

Emerging players

• Novavax: Biotechnology company developing recombinant nanoparticle vaccines against viral infectious diseases including COVID-19 and influenza. Comparable as a smaller infectious-disease-focused developer targeting viral pathogens.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Epiphany